Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Phase III Multi-Center Study Evaluating the Safety and Efficacy of BF-200 ALA Versus Placebo in the Treatment of Actinic Keratosis (AK) When Using PDT

NCT02799082 is registered in ClinicalTrials.gov with Biofrontera Bioscience GmbH as lead sponsor.

NCT NCT02799082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02799082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Phase III Multi-Center Study Evaluating the Safety and Efficacy of BF-200 ALA Versus Placebo in the Treatment of Actinic Keratosis (AK) When Using PDT
Lead sponsor
Biofrontera Bioscience GmbH
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2007
Completion date
October 31, 2008
Enrollment
122 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

actinic keratosis